Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ABBOTT LABORATORIES

(ABT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Abbott Laboratories 2Q Sales Rise, Beat Analysts' Expectations

07/22/2021 | 07:54am EDT

By Dave Sebastian

Abbott Laboratories said its profit rose for the second quarter as it booked sales growth across its four major business areas.

The Abbott Park, Ill.-based healthcare-products company on Thursday posted net income of $1.19 billion, compared with $537 million in the prior year. Earnings were 66 cents a share, compared with 30 cents a share in the year-ago period.

Adjusted earnings were $1.17 a share. Net sales rose almost 40% to $10.22 billion.

Analysts polled by FactSet were expecting adjusted earnings of $1.02 a share on sales of $9.69 billion.

Diagnostics sales rose about 63% during the quarter, the company said. Global Covid-19 testing-related sales were $1.3 billion for the period, it added.

"Excluding Covid testing-related sales, our sales grew more than 11 percent on an organic basis compared to pre-pandemic levels in the second quarter of 2019," President and Chief Executive Robert Ford said.

The company said it continues to expect full-year earnings from continuing operations of $2.75 a share to $2.95 a share, or $4.30 a share to $4.50 a share on an adjusted basis.

Write to Dave Sebastian at dave.sebastian@wsj.com

(END) Dow Jones Newswires

07-22-21 0753ET

All news about ABBOTT LABORATORIES
09/23ABBOTT : Hosts Conference Call for Third-Quarter Earnings
PR
09/20GLOBAL MARKETS LIVE : Universal Music Group, China Evergrande, ENI, Prudential, Microsoft...
09/20ABBOTT LABORATORIES : Gets FDA Clearance for Portico with FlexNav Transcatheter Aortic Val..
MT
09/20Abbott Receives FDA Approval for Minimally Invasive Portico with FlexNav TAVR System to..
CI
09/15ABBOTT LABORATORIES : to Pay Quarterly Cash Dividend of $0.45 a Share on Nov. 15 to Shareh..
MT
09/15ABBOTT : Declares 391st Consecutive Quarterly Dividend
PR
09/15Abbott Laboratories Declares Quarterly Dividend, Payable on November 15, 2021
CI
09/13GLOBAL MARKETS LIVE : Valneva, Walt Disney, ViacomCBS, General Motors, Amazon...
09/13INSIDER SELL : Abbott Laboratories
MT
09/10QIAGEN N : 3M, Qiagen to comply with Biden's COVID-19 vaccination, test mandate
RE
More news
Analyst Recommendations on ABBOTT LABORATORIES
More recommendations
Financials (USD)
Sales 2021 39 807 M - -
Net income 2021 5 837 M - -
Net Debt 2021 8 454 M - -
P/E ratio 2021 36,5x
Yield 2021 1,42%
Capitalization 214 B 214 B -
EV / Sales 2021 5,58x
EV / Sales 2022 5,56x
Nbr of Employees 109 000
Free-Float 88,8%
Chart ABBOTT LABORATORIES
Duration : Period :
Abbott Laboratories Technical Analysis Chart | ABT | US0028241000 | MarketScreener
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 24
Last Close Price 120,58 $
Average target price 130,04 $
Spread / Average Target 7,85%
EPS Revisions
Managers and Directors
Robert B. Ford President, CEO, Chief Operating Officer & Director
Robert Emmett Funck Chief Financial Officer & Executive VP-Finance
Miles D. White Executive Chairman
Sabina Ewing Chief Investment Officer, VP-Business & Technology
Roxanne Schuh Austin Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ABBOTT LABORATORIES10.13%213 766
MEDTRONIC PLC9.91%174 982
BECTON, DICKINSON AND COMPANY0.48%72 711
HOYA CORPORATION29.36%62 143
ALIGN TECHNOLOGY, INC.31.19%57 302
SARTORIUS STEDIM BIOTECH77.82%55 891